<ѻýҕl>Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patientsѻýҕl> Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
<ѻýҕl>Completely Oral Regimen Effective, Feasible in APLѻýҕl> 97% of patients alive and relapse-free at 3 years Dec 10, 2023
<ѻýҕl>Non-Covalent BTK Inhibitor Approved for CLLѻýҕl> Response rates with pirtobrutinib reached 72% in heavily pretreated patient population Dec 04, 2023
<ѻýҕl>Charting the Course: From Young Adult Leukemia Patient to Oncologistѻýҕl> My experience shaped how I care for patients today Dec 03, 2023
<ѻýҕl>FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapyѻýҕl> Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
<ѻýҕl>Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALLѻýҕl> However, it may benefit children at increased risk of thrombosis Nov 20, 2023
<ѻýҕl>Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachiaѻýҕl> News, features, and commentary about cancer-related issues Nov 03, 2023
<ѻýҕl>Soap to Fight Skin Cancer; $1,000 Early Cancer Detection Test; FDA Approval in MDSѻýҕl> News, features, and commentary about cancer-related issues Oct 27, 2023
<ѻýҕl>Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatmentѻýҕl> News, features, and commentary about cancer-related issues Oct 19, 2023
<ѻýҕl>Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Liveѻýҕl> News, features, and commentary about cancer-related issues Oct 06, 2023
<ѻýҕl>Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screeningѻýҕl> News, features, and commentary about cancer-related issues Sep 28, 2023
<ѻýҕl>Frontline Combo Yields High Remission Rate in Hairy Cell Leukemiaѻýҕl> And almost all complete responders in small trial achieved MRD negativity Sep 25, 2023
<ѻýҕl>FLT3 Inhibitor Improves AML Survival With or Without Stem-Cell Transplantѻýҕl> Best outcomes with transplantation, but non-transplant patients also benefited from quizartinib Sep 11, 2023
<ѻýҕl>Early Major Response to Ponatinib in Pretreated CML Portends Better Outcomesѻýҕl> Molecular or cytogenetic response at 3 months correlated with better survival Sep 08, 2023
<ѻýҕl>Intensive Pretransplant Consolidation in Older AML Fails to Improve Resultsѻýҕl> Newer therapies and strategies might show more promise for boosting survival Sep 07, 2023
<ѻýҕl>Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Careѻýҕl> News, features, and commentary about cancer-related issues Sep 07, 2023
<ѻýҕl>More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adultsѻýҕl> Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival Sep 07, 2023
<ѻýҕl>Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLLѻýҕl> 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
<ѻýҕl>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancerѻýҕl> News, features, and commentary about cancer-related issues Jun 29, 2023
<ѻýҕl>No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLLѻýҕl> Study suggests "watch and wait" should remain standard of care Jun 28, 2023
<ѻýҕl>Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivorsѻýҕl> A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
<ѻýҕl>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortagesѻýҕl> News, features, and commentary about cancer-related issues Jun 15, 2023
<ѻýҕl>Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALLѻýҕl> One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
<ѻýҕl>CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trialѻýҕl> All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
<ѻýҕl>Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patientsѻýҕl> 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
<ѻýҕl>Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AMLѻýҕl> But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
<ѻýҕl>FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemiaѻýҕl> Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
<ѻýҕl>Blinatumomab Plus Chemo Effective in Aggressive Infant ALLѻýҕl> Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
<ѻýҕl>Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALLѻýҕl> Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
<ѻýҕl>The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Marketѻýҕl> New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
<ѻýҕl>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCTѻýҕl> Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<ѻýҕl>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignanciesѻýҕl> Most patients had no recurrence of their original intolerance event Jan 10, 2023
<ѻýҕl>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematologyѻýҕl> After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<ѻýҕl>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCTѻýҕl> Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<ѻýҕl>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLLѻýҕl> Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<ѻýҕl>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALLѻýҕl> Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<ѻýҕl>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCTѻýҕl> Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<ѻýҕl>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCTѻýҕl> "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<ѻýҕl>Year in Review: Acute Lymphoblastic Leukemiaѻýҕl> New ways to use CAR T-cell therapy and treatment de-intensification strategies Dec 05, 2022
<ѻýҕl>New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemiaѻýҕl> Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022